75920-0464 NDC - BLOWFISH (ASPIRIN, CAFFEINE)

Drug Information

Product NDC: 75920-0464

Proprietary Name: Blowfish

Non Proprietary Name: Aspirin, Caffeine

Active Ingredient(s):
  • 500 mg/1 ASPIRIN;
  • 60 mg/1 CAFFEINE


Administration Route(s): ORAL

Dosage Form(s): TABLET, EFFERVESCENT

Pharmacy Class(es):
  • Anti-Inflammatory Agents;
  • Non-Steroidal [CS];
  • Central Nervous System Stimulant [EPC];
  • Central Nervous System Stimulation [PE];
  • Cyclooxygenase Inhibitors [MoA];
  • Decreased Platelet Aggregation [PE];
  • Decreased Prostaglandin Production [PE];
  • Methylxanthine [EPC];
  • Nonsteroidal Anti-inflammatory Drug [EPC];
  • Platelet Aggregation Inhibitor [EPC];
  • Xanthines [CS]

Labeler Information

Labeler Name: Rally Labs LLC
Product Type: HUMAN OTC DRUG
FDA Application Number: part343
Marketing Category: OTC MONOGRAPH NOT FINAL
Start Marketing Date:7/23/2011

Package Information

No. Package Code Package Description Billing Unit
175920-0464-12 TABLET, EFFERVESCENT in 1 BOX (75920-0464-1)
275920-0464-220 TABLET, EFFERVESCENT in 1 BAG (75920-0464-2)
375920-0464-440 TABLET, EFFERVESCENT in 1 BAG (75920-0464-4)
475920-0464-520 TABLET, EFFERVESCENT in 1 BOX (75920-0464-5)
575920-0464-64 TABLET, EFFERVESCENT in 1 BOX (75920-0464-6)
675920-0464-720 TABLET, EFFERVESCENT in 1 BOX (75920-0464-7)
775920-0464-812 TABLET, EFFERVESCENT in 1 BOX (75920-0464-8)

NDC Record

Field Name Field Value Definition
PRODUCT NDC75920-0464The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN OTC DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEBlowfishThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEAspirin, CaffeineThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMETABLET, EFFERVESCENTThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE7/23/2011This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEOTC MONOGRAPH NOT FINALProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERpart343This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMERally Labs LLCName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEASPIRIN; CAFFEINEAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH500; 60 
ACTIVE INGRED UNITmg/1; mg/1 
PHARM CLASSESAnti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/1/2023